GOSSAMER BIO INC

Insider buys 2.9 million Gossamer Bio options at zero cost, betting on seralutinib’s FDA approval and a price jump above the 52‑week low.

Insider buying of zero‑cost options at Gossamer Bio signals management’s confidence, hinting at a future price rise despite current low valuation.

Insider buying spurs optimism for Gossamer Bio’s oncology pipeline; executives buying options signal confidence amid volatility.